Trials / Recruiting
RecruitingNCT06551207
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Fuquinitinib Combined With Cardonilizumab and SBRT Versus Fuquinitinib in Third-line and Post-line Treatment of Metastatic Colorectal Cancer: a Randomized, Controlled, Open, Multicenter Clinical Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Liu Huang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An assessment of 6-month progression-free survival in patients with mCRC with third-line and postline metastatic colorectal cancer in combination with cardonilizumab and fuquinitinib and SBRT compared with fuquinitinib monotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib | Fruquintinib:5mg ,qd,po, d1-d14, q3w |
| DRUG | Cadonilimab | Cadonilimab:10mg/kg, ivgtt, d1, q3w |
| RADIATION | SBRT | SBRT:8-10Gy×5F, god, in 10 days |
Timeline
- Start date
- 2024-08-20
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
- First posted
- 2024-08-13
- Last updated
- 2024-08-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06551207. Inclusion in this directory is not an endorsement.